Joshua Richter

4.4k total citations
139 papers, 1.6k citations indexed

About

Joshua Richter is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Joshua Richter has authored 139 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Hematology, 76 papers in Oncology and 69 papers in Molecular Biology. Recurrent topics in Joshua Richter's work include Multiple Myeloma Research and Treatments (117 papers), Protein Degradation and Inhibitors (54 papers) and Peptidase Inhibition and Analysis (29 papers). Joshua Richter is often cited by papers focused on Multiple Myeloma Research and Treatments (117 papers), Protein Degradation and Inhibitors (54 papers) and Peptidase Inhibition and Analysis (29 papers). Joshua Richter collaborates with scholars based in United States, United Kingdom and France. Joshua Richter's co-authors include Sundar Jagannath, Shambavi Richard, Deepu Madduri, Ajai Chari, Samir Parekh, Hearn Jay Cho, Guido Lancman, Larysa Sanchez, Madhav V. Dhodapkar and Ajai Chari and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Joshua Richter

131 papers receiving 1.6k citations

Peers

Countries citing papers authored by Joshua Richter

Since Specialization

Citations

This map shows the geographic impact of Joshua Richter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Richter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Richter more than expected).

Fields of papers citing papers by Joshua Richter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Richter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Richter. The network helps show where Joshua Richter may publish in the future.

Co-authorship network of co-authors of Joshua Richter

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Richter. A scholar is included among the top collaborators of Joshua Richter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Richter. Joshua Richter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy 2025 ·Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), Adolfo Aleman, (unknown), Erin Moshier, Adriana Rossi, Shambavi Richard, Gurbakhash Kaur, Joshua Richter, Larysa Sanchez, Cesar Rodriguez, Hearn Jay Cho, Shafinaz Hussein, (unknown), Lewis R. Silverman, Sundar Jagannath, Samir Parekh, Santiago Thibaud	1
2	Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis 2025 ·American Journal of Hematology ·Joshua Richter, Ajay K. Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, (unknown), (unknown), Leanne Cooper, (unknown), Nick Ballew, (unknown), Natalie Boytsov, (unknown), Simon McNamara	1
3	Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study 2024 ·Annals of Hematology ·Csaba Siffel, Joshua Richter, Colin Anderson‐Smits, (unknown), (unknown), Drishti Shah, Matthew S. Davids	2
4	Soluble B‐cell maturation antigen in multiple myeloma 2024 ·American Journal of Hematology ·Bruno Almeida Costa, (unknown), Alexander M. Lesokhin, Joshua Richter	7
5	Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). 2024 ·Journal of Clinical Oncology ·Sundar Jagannath, Hans C. Lee, Joshua Richter, Jeffrey A. Zonder, James E. Hoffman, Zheng‐Yi Zhou, (unknown), Mirko Fillbrunn, (unknown), (unknown), Qiufei Ma, (unknown), Yingxin Xu, (unknown), James Harnett, Tito Roccia, Glenn S. Kroog, Karen Rodriguez-Lorenc, Yariv Houvras, Naresh Bumma	1
6	Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead 2024 ·Seminars in Hematology ·Tarek H. Mouhieddine, Bruno Almeida Costa, Joshua Richter	2
7	Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Joshua Richter, Matthew S. Davids, Colin Anderson‐Smits, (unknown), (unknown), Michael Hüll, (unknown), Drishti Shah, Csaba Siffel	3
8	Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody 2023 ·Cancer Management and Research ·(unknown), Joshua Richter	9
9	Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study 2023 ·Blood ·Lucia Chen, Santiago Thibaud, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa Sanchez, Cesar Rodriguez, Adriana Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath	0
10	IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies 2023 ·Blood Cancer Discovery ·Guido Lancman, (unknown), (unknown), Lisa Avery, (unknown), (unknown), Hearn Jay Cho, Samir Parekh, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari	56
11	T‐cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails! 2023 ·British Journal of Haematology ·Joshua Richter	0
12	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma 2022 ·JCO Precision Oncology ·Paula Restrepo, Sherry Bhalla, Yogita Ghodke‐Puranik, Adolfo Aleman, Violetta V. Leshchenko, David T. Melnekoff, Sarita Agte, Joy Jiang, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J. Walker, Yosef Landesman, Alessandro Laganà, Samir Parekh	14
13	Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) 2021 ·Blood ·Jeffrey A. Zonder, Joshua Richter, Naresh Bumma, Jason Brayer, James E. Hoffman, William Bensinger, Ka Lung Wu, Linzhi Xu, (unknown), Anita Boyapati, Manish Sharma, Karen Rodriguez Lorenc, Glenn S. Kroog, Madhav V. Dhodapkar, Suzanne Lentzsch, Dennis Cooper, Sundar Jagannath	27
14	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Guido Lancman, (unknown), (unknown), Samantha E. Jacobs, John T. Doucette, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Joshua Richter, Ajai Chari	18
15	The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Kunal K. Sindhu, Erin Moshier, Joshua Richter, Shambavi Richard, Ajai Chari, Larysa Sanchez, Samir Parekh, Hearn Jay Cho, Sundar Jagannath, Kavita V. Dharmarajan	6
16	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Siyang Leng, Erin Moshier, Douglas Tremblay, Liangyuan Hu, Noa Biran, (unknown), Samir Parekh, (unknown), Deepu Madduri, Joshua Richter, Bart Barlogie, Sundar Jagannath, Ajai Chari	2
17	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Tarek H. Mouhieddine, Yasir Ahmad, Bart Barlogie, Sundar Jagannath, Julie Teruya‐Feldstein, Joshua Richter	3
18	Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma 2018 ·Blood ·Alessandro Laganà, Dan Fu Ruan, David T. Melnekoff, Violetta V. Leshchenko, Deepak Perumal, Adeeb Rahman, (unknown), Ying Song, Jonathan J. Keats, (unknown), Daniel Auclair, Deepu Madduri, Joshua Richter, Ajai Chari, Hearn Jay Cho, Bart Barlogie, Sundar Jagannath, Joel T. Dudley, Amir Horowitz, Samir Parekh	3
19	E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients 2018 ·Blood ·Alessandro Laganà, (unknown), (unknown), Violetta V. Leshchenko, Marsha Crochiere, Yosef Landesman, David T. Melnekoff, (unknown), Deepak Perumal, Deepu Madduri, Joshua Richter, Ajai Chari, Hearn Jay Cho, Bart Barlogie, Sundar Jagannath, Joel T. Dudley, Samir Parekh	8
20	Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen 2017 ·Blood ·Robert M. Rifkin, Ralph V. Boccia, Suman Kambhampati, Joshua Richter, Saad Z. Usmani, (unknown), (unknown), (unknown), Bingxia Wang, (unknown), (unknown), (unknown), Liviu Niculescu, Stephen J. Noga	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact